Literature DB >> 15928942

Differential activation of mitogen activated protein kinases and nuclear factor-kappaB in lipopolysaccharide-treated term and preterm amnion cells.

Hyun Sook Jung1, Bo Hyun Yoon, Jong Kwan Jun, Miha Kim, Young Ah Kim, Chong Jai Kim.   

Abstract

Intrauterine exposure to amniotic sac infection elicits an inflammatory response from the fetus, which is associated with elevated levels of fetal plasma proinflammatory cytokines, i.e. interleukin-6 (IL-6). We have recently demonstrated that the severity of fetal inflammatory response in terms of gestation period is greater in preterm fetuses than in term fetuses. The activation of mitogen activated protein kinases (MAPKs) and nuclear factor kappa B (NF-kappaB) is known to be associated with up-regulation of proinflammatory cytokine gene expression in many cell types. In the present study, therefore, we studied patterns of MAPK and NF-kappaB activation following treatment with bacterial lipopolysaccharide (LPS) in amnion cells obtained from placentas of varying gestational ages to assess whether or not MAPKs and NF-kappaB are differentially regulated during gestation. MAPK phosphorylation was investigated by immunoblot analysis with phosphospecific antibodies. Transient phosphorylations of extracellular signal-regulated kinase (ERK) 1/2 and c-Jun N-terminal kinase (JNK) were observed in LPS-treated amnion cells, with the degree of phosphorylation being more pronounced in preterm cases. The results of NF-kappaB-dependent reporter gene expression and electrophoretic mobility shift assay (EMSA) of NF-kappaB were similar to those of ERK 1/2 and JNK activity. To assess whether the results of in vitro observations reflected in vivo results, we further analyzed amniotic fluid and cord blood IL-6 levels in preterm deliveries with placental inflammation. The analysis also revealed a significantly higher level of IL-6 in cases of </=31 weeks gestation when compared with those of more than 31 weeks (P<0.001). All these findings strongly suggest that there is an inverse relationship between gestational age and fetal inflammatory response during human gestation, and that differences in the intensity of MAPK activation and NF-kappaB-dependent transcription pathways are elements of the major underlying mechanism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15928942     DOI: 10.1007/s00428-005-1248-9

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  38 in total

1.  The prevalence and distribution of acute placental inflammation in uncomplicated term pregnancies.

Authors:  C M Salafia; C Weigl; L Silberman
Journal:  Obstet Gynecol       Date:  1989-03       Impact factor: 7.661

2.  Assessment of cord blood IL-6 levels as an indicator of neonatal sepsis.

Authors:  A Perenyi; R Johann-Liang; J J Stavola
Journal:  Am J Perinatol       Date:  1999       Impact factor: 1.862

3.  High expression of tumor necrosis factor-alpha and interleukin-6 in periventricular leukomalacia.

Authors:  B H Yoon; R Romero; C J Kim; J N Koo; G Choe; H C Syn; J G Chi
Journal:  Am J Obstet Gynecol       Date:  1997-08       Impact factor: 8.661

4.  Identification and characterization of an IkappaB kinase.

Authors:  C H Régnier; H Y Song; X Gao; D V Goeddel; Z Cao; M Rothe
Journal:  Cell       Date:  1997-07-25       Impact factor: 41.582

5.  Differences in the fetal interleukin-6 response to microbial invasion of the amniotic cavity between term and preterm gestation.

Authors:  B H Yoon; R Romero; J Moon; T Chaiworapongsa; J Espinoza; Y M Kim; S Edwin; J C Kim; N Camacho; E Bujold; R Gomez
Journal:  J Matern Fetal Neonatal Med       Date:  2003-01

6.  Association between funisitis and elevated interleukin-6 in cord blood.

Authors:  N Naccasha; R Hinson; A Montag; M Ismail; L Bentz; R Mittendorf
Journal:  Obstet Gynecol       Date:  2001-02       Impact factor: 7.661

7.  Amniotic fluid cytokines (interleukin-6, tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8) and the risk for the development of bronchopulmonary dysplasia.

Authors:  B H Yoon; R Romero; J K Jun; K H Park; J D Park; F Ghezzi; B I Kim
Journal:  Am J Obstet Gynecol       Date:  1997-10       Impact factor: 8.661

8.  A spontaneous induction of fetal membrane prostaglandin production precedes clinical labour.

Authors:  N L Brown; S A Alvi; M G Elder; P R Bennett; M H Sullivan
Journal:  J Endocrinol       Date:  1998-05       Impact factor: 4.286

9.  Regulation of phospholipase isozymes by nuclear factor-kappaB in human gestational tissues in vitro.

Authors:  Martha Lappas; Michael Permezel; Harry M Georgiou; Gregory E Rice
Journal:  J Clin Endocrinol Metab       Date:  2004-05       Impact factor: 5.958

10.  Kinetics of mitogen-activated protein kinase family in lipopolysaccharide-stimulated mouse Kupffer cells and their role in cytokine production.

Authors:  Jian-Xin Jiang; Yu Zhang; San-He Ji; Peifang Zhu; Zheng-Guo Wang
Journal:  Shock       Date:  2002-10       Impact factor: 3.454

View more
  4 in total

Review 1.  Targeting inflammation to prevent bronchopulmonary dysplasia: can new insights be translated into therapies?

Authors:  Clyde J Wright; Haresh Kirpalani
Journal:  Pediatrics       Date:  2011-06-06       Impact factor: 7.124

2.  Amniotic Fluid Soluble Myeloid Differentiation-2 (sMD-2) as Regulator of Intra-amniotic Inflammation in Infection-induced Preterm Birth.

Authors:  Antonette T Dulay; Catalin S Buhimschi; Guomao Zhao; Emily A Oliver; Sonya S Abdel-Razeq; Lydia L Shook; Mert O Bahtiyar; Irina A Buhimschi
Journal:  Am J Reprod Immunol       Date:  2015-01-21       Impact factor: 3.886

Review 3.  Bench-to-bedside review: Neonatal sepsis-redox processes in pathogenesis.

Authors:  Ivan Spasojević; Budimir Obradović; Snežana Spasić
Journal:  Crit Care       Date:  2012-05-10       Impact factor: 9.097

4.  Increased Soluble Epoxide Hydrolase in Human Gestational Tissues from Pregnancies Complicated by Acute Chorioamnionitis.

Authors:  Tai-Ho Hung; Szu-Fu Chen; Chun-Hu Wu; Chuan-Chi Kao; Chung-Pu Wu
Journal:  Mediators Inflamm       Date:  2019-12-05       Impact factor: 4.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.